Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Development of cardiovascular disease is one of the major complications of type 2 diabetes mellitus ( T2DM ). The chronic hyperglycaemic state is often accompanied by dyslipidaemia, hypertension, low‐grade systemic inflammation and oxidative stress which collectively result in a high risk of micro‐ and macrovascular complications. Current glucose‐lowering agents do not sufficiently address fore‐mentioned macrovascular‐risk factors. Recently, new therapeutic agents were introduced, based on the incretin hormone glucagon‐like peptide‐1 ( GLP ‐1), that is, the GLP ‐1 receptor agonists ( GLP‐1RA ) and dipeptidyl‐peptidase 4 ( DPP ‐4) inhibitors. Beside its effect on pancreatic insulin secretion, GLP ‐1 exerts several extra‐pancreatic effects such as slowing down gastric emptying, promoting satiety and reducing food intake and weight loss. Also, GLP ‐1 and GLP‐1RA were shown to improve cardiovascular‐risk profiles, by reducing body fat content, blood pressure, circulating lipids and inflammatory markers in patients with T2DM . This review summarizes the presently known evidence with regard to extra‐pancreatic effects of the incretin‐based agents, focusing on the actions that improve the cardiovascular‐risk profile. We present available data from clinical trials of at least 24 week duration, but also findings from small‐sized clinical ‘proof of principle’ studies. We conclude that GLP ‐1 RA and to a lesser extent DPP ‐4 inhibitors are promising agents with regard to their effects on body weight, blood pressure and lipids, which collectively ameliorate the cardiovascular‐risk profile and as such may have added value in the treatment of T2DM . However, large‐sized long‐term outcome studies are warranted to show the true added value of these agents in the treatment of patients with T2DM .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationGeneral and abdominal adiposity and risk of death in Europe
Pischon, T., Boeing, H., Hoffmann, K., Bergmann, M., Schulze, M. B., Overvad, K., van der Schouw, Y. T., Spencer, E., Moons, K. G. M., Tjønneland, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801891 · Cited by 2,155 · cited 1×
“Both general obesity and abdominal adiposity are associated with an increased cardiovascular risk in humans [16].”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“87 kg, non-significant (NS) [62]) and exenatide QW (liraglutide −3.”
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189 · cited 1×
“Cardiovascular disease (CVD) is a major complication of type 2 diabetes mellitus (T2DM) as a consequence of hyperglycaemiainduced micro- and macro-angiopathy [1,2].”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Cited by
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Cena, H., Chiovato, L., & Nappi, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa285 · Cited by 356
“In subjects with DM, the use of GLP-1 RA is associated with a significant reduction of glycated hemoglobin, with weight loss, a modest decrease in blood pressure, and an improvement of hyperlipidemia (75, 76).”
BackgroundInflammation meets metabolic disease: Gut feeling mediated by GLP-1
Zietek, T., & Rath, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00154 · Cited by 131
SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis
Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., & Weng, J. (2014) · Diabetes · doi:10.2337/db14-0263 · Cited by 114
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“GLP-1 receptor agonists appear to positively influence the cardiovascular risk profile (with the exception of heart-rate elevation, as discussed below) by exerting a range of additional effects, both direct and indirect (16,39,40,46).”
Background
Metadata
- Authors
- van Genugten, R. E., Möller‐Goede, D. L., van Raalte, D. H., & Diamant, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-01-21
- Volume
- 15
- Issue
- 7
- Pages
- 593-606
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2044967663
- Cited by
- 46
- References
- 47
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.12050
- The paper
- van Genugten, R. E., Möller‐Goede, D. L., van Raalte, D. H., & Diamant, M. (2013). Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.